While the approval of a dengue vaccine is a notable development, some experts urge caution regarding the limitations of this new tool. Critics warn that viewing the vaccine as a 'silver bullet' could lead to a dangerous decline in essential public health practices, such as community-led mosquito control. If the public begins to believe that a shot provides total immunity, they may become less vigilant about eliminating breeding sites, potentially leading to an increase in other mosquito-borne illnesses like Zika or Chikungunya.
There are also practical concerns regarding the logistics of a mass vaccination campaign. Dengue is a complex disease with four distinct serotypes, and the efficacy of any vaccine can vary depending on a person's prior exposure to the virus. Ensuring that the right populations receive the correct dosage at the right time requires a level of administrative precision that is difficult to maintain across diverse and densely populated regions. If the rollout is uneven, it could create a false sense of security in some areas while leaving others just as vulnerable as before.
Accountability remains a central issue for skeptics who want to see transparent data on how the vaccine performs in India's specific environmental and epidemiological context. They argue that the government must maintain rigorous post-market surveillance to track any potential side effects or shifts in viral behavior. Without a clear, long-term strategy that integrates the vaccine with ongoing sanitation and public education, the investment may not yield the expected reduction in overall disease burden.
Finally, the cost-benefit analysis of the vaccine must be carefully scrutinized. Critics suggest that funds could potentially be more effectively spent on improving urban sanitation, water management, and diagnostic infrastructure. By focusing heavily on a single medical product, the state risks neglecting the systemic improvements that are necessary to address the root causes of mosquito-borne disease outbreaks in the long run.